TAG HIV Basic Science, Vaccines, and Cure Project Blog
By Richard Jefferys, Project Director at Treatment Action Group (TAG).
recent posts
- HIV Cure Research at AIDS 2026
- In The News: CAR-T Cells for HIV
- TAG’s HIV Cure-Related Clinical Research Listing: Background on the March 2026 Update
- TAG’s HIV Cure-Related Clinical Research Listing: Background on the February 2026 Update
- TAG’s HIV Cure-Related Clinical Research Listing: Background on the December 2025 and January 2026 Updates
Category: Immune checkpoint inhibitors
-
For February 2025, there were eight updates to TAG’s listing. New Additions Four new protocols were added. In Toronto, a trial is underway that aims to assess whether the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz may be able to promote the death of HIV-infected cells. The rationale derives from evidence that certain NNRTI molecules can…
-
For January 2025 there were only two updates to TAG’s listing, likely reflecting the holiday period since the December update. New Links to Study Results Both updates were links to newly available results from studies in the listing. At the HIV Persistence Workshop last December in Fort Lauderdale, James McMahon and colleagues presented preliminary information…
-
There were 14 updates to TAG’s listing for October 2024. New Additions Two new clinical trials were identified in registries, neither yet open for enrollment: Researchers in the UK are initiating a study of the anti-CMV drug letermovir primarily to assess effects on T cell activation in people with HIV on antiretroviral therapy (ART). Markers…
-
For September 2024 there are six updates to TAG’s listing: New Additions One new study was registered over the past month, a protocol for conducting analytical treatment interruptions (ATIs) in people with HIV who’ve received successful stem transplants to treat cancers. The criteria require that the stem cell transplants were sourced from donors homozygous for…
-
There are 14 updates in the June 2024 revision to TAG’s listing. New Additions Three newly registered studies have been added: two interventional and one observational. The German company Hookipa Biotech is sponsoring a clinical trial assessing two therapeutic HIV vaccine candidates based on an arenavirus vector platform in people with HIV on antiretroviral…